169 related articles for article (PubMed ID: 32464192)
21. Neuroprotection in glaucoma--delusion, reality or hope?
Dimovska-Jordanova A
Prilozi; 2012; 33(2):163-73. PubMed ID: 23425879
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotection in glaucoma: present and future.
Chen SD; Wang L; Zhang XL
Chin Med J (Engl); 2013; 126(8):1567-77. PubMed ID: 23595396
[TBL] [Abstract][Full Text] [Related]
23. Glaucoma, apoptosis, and neuroprotection.
McKinnon SJ
Curr Opin Ophthalmol; 1997 Apr; 8(2):28-37. PubMed ID: 10168354
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotection for treatment of glaucoma in adults.
Sena DF; Lindsley K
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006539. PubMed ID: 28122126
[TBL] [Abstract][Full Text] [Related]
25. Animal and culture models of glaucoma for studying neuroprotection.
Levin LA
Eur J Ophthalmol; 2001; 11 Suppl 2():S23-9. PubMed ID: 11592527
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
Zhong L; Bradley J; Schubert W; Ahmed E; Adamis AP; Shima DT; Robinson GS; Ng YS
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1212-8. PubMed ID: 17325165
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotection in glaucoma using calpain-1 inhibitors: regional differences in calpain-1 activity in the trabecular meshwork, optic nerve and implications for therapeutics.
Govindarajan B; Laird J; Sherman R; Salomon RG; Bhattacharya SK
CNS Neurol Disord Drug Targets; 2008 Jun; 7(3):295-304. PubMed ID: 18673213
[TBL] [Abstract][Full Text] [Related]
28. Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: the Friedenwald lecture.
Schwartz M
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1407-11. PubMed ID: 12657572
[No Abstract] [Full Text] [Related]
29. BDNF impairment is associated with age-related changes in the inner retina and exacerbates experimental glaucoma.
Gupta V; You Y; Li J; Gupta V; Golzan M; Klistorner A; van den Buuse M; Graham S
Biochim Biophys Acta; 2014 Sep; 1842(9):1567-78. PubMed ID: 24942931
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy for retinal ganglion cell neuroprotection in glaucoma.
Wilson AM; Di Polo A
Gene Ther; 2012 Feb; 19(2):127-36. PubMed ID: 21975466
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective therapies for glaucoma.
Song W; Huang P; Zhang C
Drug Des Devel Ther; 2015; 9():1469-79. PubMed ID: 25792807
[TBL] [Abstract][Full Text] [Related]
32. Optic nerve and neuroprotection strategies.
Osborne NN; Chidlow G; Layton CJ; Wood JP; Casson RJ; Melena J
Eye (Lond); 2004 Nov; 18(11):1075-84. PubMed ID: 15534592
[TBL] [Abstract][Full Text] [Related]
33. Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma.
Yadav KS; Sharma S; Londhe VY
Life Sci; 2020 Feb; 243():117303. PubMed ID: 31953158
[TBL] [Abstract][Full Text] [Related]
34. [Pay attention to the secondary optic neuropathy and the safe appropriate applications of optic neuroprotection].
Zhong Y
Zhonghua Yan Ke Za Zhi; 2016 Dec; 52(12):881-884. PubMed ID: 27998451
[TBL] [Abstract][Full Text] [Related]
35. The potential of neuroprotection in glaucoma treatment.
Osborne NN; Chidlow G; Nash MS; Wood JP
Curr Opin Ophthalmol; 1999 Apr; 10(2):82-92. PubMed ID: 10537768
[TBL] [Abstract][Full Text] [Related]
36. Virus-mediated EpoR76E Therapy Slows Optic Nerve Axonopathy in Experimental Glaucoma.
Bond WS; Hines-Beard J; GoldenMerry YL; Davis M; Farooque A; Sappington RM; Calkins DJ; Rex TS
Mol Ther; 2016 Feb; 24(2):230-239. PubMed ID: 26502777
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of N-Methyl-D-aspartate-induced Retinal Neuronal Death by Polyarginine Peptides Is Linked to the Attenuation of Stress-induced Hyperpolarization of the Inner Mitochondrial Membrane Potential.
Marshall J; Wong KY; Rupasinghe CN; Tiwari R; Zhao X; Berberoglu ED; Sinkler C; Liu J; Lee I; Parang K; Spaller MR; Hüttemann M; Goebel DJ
J Biol Chem; 2015 Sep; 290(36):22030-48. PubMed ID: 26100636
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotection in glaucoma: recent advances and clinical translation.
Guymer C; Wood JP; Chidlow G; Casson RJ
Clin Exp Ophthalmol; 2019 Jan; 47(1):88-105. PubMed ID: 29900639
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of neuroprotection and applications in ocular disease.
Eur J Ophthalmol; 1999; 9 Suppl 1():S52-81; quiz S82-4. PubMed ID: 10230609
[No Abstract] [Full Text] [Related]
40. In glaucoma, should enthusiasm about neuroprotection be tempered by the experience obtained in other neurodegenerative disorders?
Haefliger IO; Fleischhauer JC; Flammer J
Eye (Lond); 2000 Jun; 14 ( Pt 3B)():464-72. PubMed ID: 11026975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
